Ocugen, Inc. develops gene therapies for blindness diseases through a modifier gene therapy platform designed to address inherited and multifactorial retinal disorders. Company news commonly covers programs such as OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy secondary to dry age-related macular degeneration, and OCU410ST for Stargardt disease.
Recurring updates include clinical trial data and dosing milestones, clinical and regulatory disclosures, operating and financial results, investor presentations, convertible-note financing, shareholder voting matters, capital-structure actions, and governance matters tied to the company's Nasdaq-listed common stock.
Ocugen (OCGN) will present its modifier gene therapy platform at investor and industry conferences in November 2026. Chairman, CEO and Co-Founder Dr. Shankar Musunuri will give a presentation at the Stifel 2026 Healthcare Conference in New York on November 12 and join a panel at Cell & Gene Leaders Live 2026 in London on November 15. The Stifel webcast will be available on Ocugen’s investor website, with a replay available for 30 days following the event.
Ocugen (OCGN) will report third quarter 2026 financial results and provide a business update on November 4, 2026. The conference call and live webcast will begin at 8:30 a.m. ET. Related materials will be available on the company’s investor website before the call, with a replay and archived webcast available afterward.
Ocugen (NASDAQ: OCGN) executed an agreement granting Roots Pharmaceutical exclusive regional rights to OCU400 for retinitis pigmentosa, an inherited vision-loss disease. The agreement involves Roots’ partner, Al-Dhow International Holding, and covers the Middle East and North Africa. Subject to agreement terms, Ocugen will receive an upfront license fee and potential initial development milestone payments totaling up to $4 million, potential sales milestones of up to $255 million, and royalties equal to 22% of OCU400 net sales generated by Roots. Ocugen will manufacture commercial supply under a related supply agreement.
OCU400 is advancing through the Phase 3 liMeliGhT trial. Ocugen expects topline results in the first quarter of 2027, followed by global regulatory submissions, including applications in the U.S. and Europe.
Ocugen (OCGN) appointed Jolanda Crombach as General Manager of its newly established European affiliate, headquartered in Amsterdam, Netherlands. She will lead development of the affiliate’s team and infrastructure to support three late-stage gene therapy programs.
OCU400 targets retinitis pigmentosa, OCU410 targets geographic atrophy secondary to dry age-related macular degeneration, and OCU410ST targets Stargardt disease. All three programs are in Phase 3. Ocugen expects data readouts in 2027 and 2028, followed by global regulatory submissions, including applications for marketing authorization in Europe. Crombach most recently served as Managing Director and Board Member of Moderna Netherlands.
Ocugen (OCGN) will present its modifier gene therapy platform at upcoming scientific conferences in Vienna and New Orleans.
The schedule includes a company overview at Euretina Innovation Spotlight on September 30, 2026, and presentations at the 26th Euretina Congress on October 1–4 covering geographic atrophy and Stargardt disease. At the American Academy of Ophthalmology Annual Meeting on October 9–12, presentations will cover twelve-month safety and efficacy results from the Phase 2 ArMaDa trial of OCU410, the Phase 1 GARDian1 trial of OCU410ST in Stargardt disease, and three-year visual function results for OCU400 in retinitis pigmentosa.
Ocugen (OCGN) will participate in two October 2026 investor and industry conferences featuring Chairman and CEO Shankar Musunuri.
Musunuri will moderate a financing panel at H.C. Wainwright’s Biotech on Tap in Munich on October 1. He will also participate in a panel on cell and gene therapy approval and commercialization at Cell & Gene Meeting on the Mesa in Phoenix on October 6.
Ocugen (OCGN) announced on September 25, 2026, that OCU400 received provisional approval and priority designation in The Bahamas.
OCU400 is an investigational gene therapy for retinitis pigmentosa. Ocugen plans to supply it through an expanded access program and aims to treat the first patient within 90 days following full approval by the Longevity and Regenerative Therapies Board. The therapy is in Phase 3 testing. Ocugen expects topline data in the first quarter of 2027 and plans to submit a Biologics License Application in the second quarter of 2027.
Ocugen (NASDAQ: OCGN) reported dosing the first patient in ArMaDa3, its global, single Phase 3 registrational trial of OCU410, a one-time subretinal modifier gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration. The 237‑patient, randomized 2:1 study compares OCU410 to an untreated control, using GA lesion growth rate by fundus autofluorescence as the primary endpoint and functional vision and ellipsoid zone preservation as key secondary endpoints.
According to Ocugen, the FDA granted RMAT designation to OCU410 on July 29, 2026, and aligned with a single, adequate and well‑controlled Phase 3 to support a planned BLA filing in 2028. Phase 2 12‑month data showed a statistically significant 31% reduction in GA lesion growth at the medium dose versus control and no OCU410‑related serious adverse events or adverse events of special interest.
Ocugen (NASDAQ: OCGN) will highlight its modifier gene therapy platform and clinical progress at three events in September 2026. The company is participating in the Citi 2026 Biopharma Back to School Conference on September 9 and the H.C. Wainwright 28th Annual Global Investment Conference on September 15, both as fireside chats featuring Chairman and CEO Dr. Shankar Musunuri. On September 24, Ocugen will present 12‑month randomized Phase 2 ArMaDa results for subretinal OCU410 gene therapy in geographic atrophy at The Retina Society 59th Annual Scientific Meeting, presented by Dr. Raj K. Maturi. Webcasts of the Citi and H.C. Wainwright sessions will be accessible via the Investors section of Ocugen’s website, with replays available for 30 days.
Ocugen (NASDAQ: OCGN) reported second quarter 2026 results and a broad business update. FDA cleared the Phase 3 ArMaDa3 trial of OCU410 for geographic atrophy, based on 12‑month Phase 2 data showing a statistically significant 31% reduction in lesion growth at the planned Phase 3 dose, and granted RMAT designation, with BLA/MAA filings targeted for 2028.
Enrollment was completed in pivotal trials of OCU400 for retinitis pigmentosa (N=140) and OCU410ST for Stargardt disease (N=63), with topline data expected in 1Q and 2Q 2027, respectively. Ocugen signed a binding term sheet with Roots Pharmaceutical and Al‑Dhow International Holding for an exclusive OCU400 license in MENA, including up to $255 million in sales milestones and a 22% royalty on net sales.
The company closed a $130.0 million 6.75% convertible senior notes offering (net proceeds ~$112.5 million), using ~$32.7 million to fully retire higher‑cost Avenue Capital debt, and extending its cash runway into 2028. As of June 30, 2026, cash and restricted cash were $100.4 million, revenue was $1.5 million, operating expenses were $17.9 million, and net loss was $24.9 million, or $0.07 per share.